Roche is shifting beyond licensing by partnering with Chinese startup Defand Therapeutics to discover new medicines. The collaboration marks a continuation of pharma’s China push, but with a different emphasis: co-development of discovery outputs rather than importing fully formed candidates. The move also signals that large pharma wants earlier-stage optionality in China—potentially reducing downstream development risk by building IP and candidate selection from the start of the discovery process. For Defand, the partnership can add funding stability and accelerate translational planning. For industry observers, the deal reinforces how global oncology and broader pipeline needs are driving new relationship models in China, where companies compete not only on assets but on innovation execution speed and platform integration.